CORE-IBD: A Multidisciplinary International Consensus Initiative to Develop a Core Outcome Set for Randomized Controlled Trials in Inflammatory Bowel Disease
Christopher Ma(University of Calgary), Niels Vande Casteele(University of California San Diego), Péter L. Lakatos(McGill University), Ellen Scherl(NewYork–Presbyterian Hospital), Remo Panaccione(University of Calgary), Stephen B. Hanauer(Northwestern University), Jean‐Frédéric Colombel(Mount Sinai Hospital), Çharles N. Bernstein(University of Manitoba), Séverine Vermeire(KU Leuven), Marla C. Dubinsky(Icahn School of Medicine at Mount Sinai), Rupert W. Leong(The University of Sydney), Vineet Ahuja(All India Institute of Medical Sciences), Peter Bossuyt(Imelda Hospital), Antonino Spinelli(Istituti di Ricovero e Cura a Carattere Scientifico), Paulo Gustavo Kotze(International Organization for Migration), Leonardo Guizzetti(Xerox (Canada)), William J. Sandborn(University of San Diego), Torsten Kucharzik(Klinikum Lüneburg), Raja Atreya(Friedrich-Alexander-Universität Erlangen-Nürnberg), Siddharth Singh(Mayo Clinic in Arizona), Richard B. Gearry(Waitaki Biosciences (New Zealand)), Julián Panés(Hospital Clínic de Barcelona), Michelle I. Smith(Washington University in St. Louis), Ailsa Hart(St Mark's Hospital), Axel Dignaß(Goethe University Frankfurt), Laurent Peyrin‐Biroulet(Délégation Centre-Est), Silvio Danese(IRCCS Ospedale San Raffaele), Matthieu Allez(Inserm), David T. Rubin(University of California System), Fernando Magro(Universidade do Porto), Claire E. Parker, Willem A. Bemelman(Vrije Universiteit Amsterdam), Geert D’Haens(Amsterdam University Medical Centers), Brian Bressler(University of British Columbia), Phillip Fleshner(Cedars-Sinai Medical Center), Édouard Louis(Centre Hospitalier Universitaire de Liège), Takayuki Yamamoto(Yokkaichi Social Insurance Hospital), Simon Travis(University of Oxford), Jurij Hanžel(University of Ljubljana), A. Hillary Steinhart(Mount Sinai Hospital), Bruce Yacyshyn(University of Alberta), Miguel Regueiro(University of Pittsburgh Medical Center), Stefanie C. McFarlane, C. Janneke van der Woude(Radboud University Nijmegen), Corey A. Siegel(Dartmouth–Hitchcock Medical Center), Amy L. Lightner(Scripps Research Institute), Zhihua Ran, Robert V. Bryant(Queen Elizabeth Hospital), Benjamin L. Cohen(Cleveland Clinic), Mark S. Silverberg(Sinai Health System)
Cited by 84
Related Papers
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
|Nature|2012|4.8k
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
A Genome-Wide Association Study Identifies <i>IL23R</i> as an Inflammatory Bowel Disease Gene
|Science|2006|3k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k